3D Systems is a holding company. Through its subsidiaries, the company provides 3D printing solutions, including 3D printers for plastics and metals, materials, software, on demand manufacturing services and digital design tools. The company's solutions support applications in a range of industries and verticals, including healthcare, aerospace, automotive and durable goods. The company's healthcare capabilities include simulation, Virtual Surgical Planning (VSP?), and printing of medical and dental devices, models, and surgical guides and instruments. The company provides 3D printing technologies including Stereolithography, Selective Laser Sintering, Direct Metal Printing, MultiJet Printing and ColorJet Printing.

Ampco-Pittsburgh manufactures and sells engineered specialty metal products and customized equipment. The company's segments are: Forged and Cast Engineered Products, which includes the company's subsidiary, Union Electric Steel Corporation, that produces ingot and forged products and focuses on the production of forged hardened steel rolls used in rolling by producers of steel, aluminum and other metals; and Air and Liquid Processing, which includes the company's subsidiary, Air & Liquid Systems Corporation, that produces custom-engineered finned tube heat exchange coils and related heat transfer products for nuclear power generation, industrial process and heating, ventilation and air conditioning industries.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, the company's therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. The company is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The company's pipeline includes, among others, ARO-AAT, a candidate for the treatment of liver disease, and ARO-APOC3, which is designed to reduce production of Apolipoprotein C-III, a component of triglyceride rich lipoproteins.

Atkore International Group is a holding company. Through its subsidiaries, the company is engaged as a manufacturer of Electrical Raceway products primarily for the non-residential construction and renovation markets and Mechanical Products and Solutions (MP&S) for the construction and industrial markets. The company's segments are: Electrical Raceway, which ufactures products that deploy, isolate and protect a structure's electrical circuitry from the original power source to the final outlet; and MP&S, which provides products and services that frame, support and secure component parts in a range of structures, equipment and systems in electrical, industrial and construction applications.

Axcella Health is a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. The company's AXA Candidates are generated from its proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism.

Beam Therapeutics operates as a biotechnology company. Through its subsidiaries, the company is a research stage biotechnology company committed to creating a new class of precision genetic medicines, based on the company's proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

Bill.com is a holding company. Through its subsidiaries, the company is a provider of software-as-a-service, cloud-based payments products, which allow users to automate accounts payable and accounts receivable transactions and enable users to easily connect with their suppliers and/or customers to do business, manage cash flows and improve back office efficiency.

Capstone Turbine develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation and distribution networks applications, including cogeneration combined heat and power. The company provides microturbines designed for commercial, industrial and onshore and offshore oil and gas applications with product offerings ranging from 30 kilowatts to one megawatt (MW) in electric power output, which can be deployed in arrays up to 10 MWs. The company also remanufactures microturbine engines and provides aftermarket parts and services, which include its Factory Protection Plan, Distributor Support System program, and long-term microturbine rentals.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. The company's product Rubraca? (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the U.S. for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. In addition to Rubraca, the company has a second product candidate in clinical development. Lucitanib is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1 through 3.

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of subcutaneously delivered ribonucleic acid (RNA) interference (RNAi)-based therapeutics using its GalXC? RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. The company's primary development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus; and an undisclosed product candidate against a rare liver disease, which is in Clinical Trial Application or Investigational New Drug application enabling studies.

Digital Turbine, through its subsidiaries, delivers end-to-end platform solution for mobile operators, application developers, device original equipment manufacturers (OEMs), and other third parties. The company's advertising business is comprised of Operator and OEM, an advertiser solution for carrier and OEM inventory comprised of services including Ignite?, a software platform with targeted media delivery and management capabilities; and Other recurring and lifecycle products, features, and services delivered on the Ignite platform. The company has launched Ignite with mobile operators and OEMs in North America, Latin America, Europe, Asia Pacific, India and Israel.

Dynatrace is a software intelligence company. The company is engaged in providing services such as application performance management, artificial intelligence for operations, cloud infrastructure monitoring, and digital experience management, with products for the information technology departments and digital business owners of medium and large businesses. The company's primary offering is the Dynatrace Software Intelligence Platform, or Dynatrace?. The company's platform provides software-as-a-service, or SaaS, with the customer option of either maintaining data in the cloud, or at the edge in customer-provisioned infrastructure, which the company refers to as Dynatrace? Managed.

Exagen operates as a commercial-stage diagnostics company. The company develops and sells diagnostic tests that addresses the diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. The company serves customers worldwide.

The ExOne is a provider of three-dimensional (3D) printing machines and 3D printed and other products, materials and services to industrial customers. The company's business primarily consists of manufacturing and selling 3D printing machines and printing products. The company provides pre-production collaboration and print products for customers through its network of production service centers and ExOne adoption centers. The company also supplies the associated materials, including consumables and replacement parts, and other services, including training and technical support that is necessary for purchasers of the company's 3D printing machines to print products.

eXp World Holdings owns and operates its main operating division which is a cloud-based international residential real estate brokerage. The company operates over the internet through its website and relies on a cloud-based platform to provide its residential real estate brokerage services. Through the company's website, buyers can search real-time property listings, and sellers list properties and gain exposure across the various geographic markets in which it operates. Additionally, the company delivers marketing, training and other support services to its brokers and agents through a combination of proprietary technology enabled services, as well as technology and support services contracted to third parties.

Fluent provides digital marketing services. The company primarily performs customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. The company delivers data and performance-based marketing executions to its clients, across a range of industries, including Financial Services, Retail and Consumer, Media and Entertainment, Staffing and Recruitment and Marketing Services. The company provides performance marketing solutions to its clients based on their desired outcomes, or specific actions in their marketing funnels, including submission of a registration form, app installation or a completed transaction.

Freeport-McMoRan is a holding company. Through its subsidiaries, the company is a mining company. The company operates assets with proven and probable reserves of copper, gold and molybdenum, and the company is a publicly traded copper producer. The company's portfolio of assets includes the Grasberg minerals district in Indonesia, copper and gold deposits; and mining operations in North America and South America, including the Morenci minerals district in Arizona and the Cerro Verde operation in Peru. The company has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines.

Fulgent Genetics is a holding company. Through its subsidiaries, the company is a technology company providing genetic testing and providing physicians with diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to provide test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels to meet customer needs. The company's test menu includes single-gene tests and panels that test for genetic conditions, including various cancers, cardiovascular diseases, neurological disorders and pediatric conditions.

iCAD is a medical technology company providing cancer detection and therapy solutions. The company has two segments: Cancer Detection, in which the company's solutions include image analysis and workflow solutions that enable healthcare personnel to identify pathologies and pinpoint the most prevalent cancers earlier, and a range of Artificial Intelligence and Computer-Aided Detection systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography; and Cancer Therapy, in which the company provides the Xoft Axxent Electronic Brachytherapy (eBx) System, an isotope-free cancer treatment platform technology for treatment of early-stage breast cancer, and among others.

Instone Real Estate Group AG is a Germany-based real estate developer specializing in residential properties. The Company's activities range from new development of apartment buildings and urban residential quarters to redevelopment and refurbishment of monument-protected properties and repurposing of former military barracks or industrial sites. The Company's portfolio consists of approximately 50 projects located in German metropolitan areas. The Company pursues further acquisitions of land for development. The Company sells the residential units it develops to owner-occupiers, private buy-to-let and institutional investors. Instone Real Estate Group AG operates through a number of branches across Germany.

Meridian Bioscience is a life science company with principal businesses in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by IVD manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The company's reportable segments are: Diagnostics, which products span a menu of testing platforms and technologies; and Life Science.

Misonix designs, manufactures and markets minimally invasive therapeutic ultrasonic medical devices. These products include the BoneScalpel? surgical system, which is used for surgical procedures involving the cutting of bone while sparing soft tissue; the SonaStar? Surgical Aspirator, which is used to emulsify and remove soft and hard tumors, primarily in the neuro and general surgery field; and the SonicOne? Wound Cleansing and Debridement System, which provides tissue debridement and cleansing of wounds and burns for removal of devitalized tissue and fibrin deposits while sparing viable cells.

NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer and viral infectious diseases. NK cells are the body's first line of defense due to their innate ability to seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules required to activate adaptive immune cells such as T-Cells. The company holds the exclusive right to commercialize activated NK cells, a commercially viable natural killer cell line, and a variety of genetically modified derivatives capable of killing cancer and virally infected cells.

Neuronetics is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company's commercial product, NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorder who have failed to achieve improvement from prior antidepressant medication in the current episode.

Ocugen is focused on its product, NeoCart?, a cell therapy that utilizes various aspects of the company's restorative cell therapy platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The company's NeoCart Phase 3 clinical trial is designed, randomized clinical trial in North America evaluating the safety and efficacy of a restorative cell therapy to treat knee cartilage damage. The company has a License and Commercialization Agreement with MEDINET Co., Ltd. with regards to the commercialization of NeoCart in Japan. HISTOGENICS (and design), its logo design and NEOCART are the company's registered trademarks.

Organogenesis Holdings is a regenerative medicine company focused on the development, manufacture and commercialization of solutions. The company's Advanced Wound Care products include Apligraf for the treatment of VLUs and DFUs; Dermagraft for the treatment of DFUs; PuraPly Antimicrobial (PuraPly AM) to address biofilm across various wound types; and Affinity and NuShield to address various wound sizes and types. The company's Surgical and Sports Medicine products include ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical application in targeted soft tissue repairs; and PuraPly AM for surgical treatment of open wounds.

Perion Network is a global technology company that delivers advertising solutions to brands and publishers. Co. provides its customers with cross-screen digital advertising through desktop, mobile (web and app) and social channels across a portfolio of media properties. Co.'s ad formats are designed to attract and engage audiences, helping brands connect to consumers and drive business results. Co.'s customers receive dedicated support throughout the full campaign cycle, including planning, creative services, client solutions, campaign management, performance and insights.

ProPetro Holding is a holding company. Through its subsidiary, the company is engaged as an oilfield services company providing hydraulic fracturing and other services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company's operations are primarily focused in the Permian Basin. In addition to its core hydraulic fracturing operations, the company provides complementary well completion and production services, including cementing, coiled tubing, flowback services and drilling. The company conducts its business through five segments: hydraulic fracturing (inclusive of acidizing), cementing, coil tubing, flowback and drilling.

Pulse Biosciences is a bioelectric medicine company. The company is pursuing regulatory clearance to market CellFX? System (CellFX). The CellFX System utilizes its Nano-Pulse Stimulation? (NPS) technology to treat various applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nanosecond duration pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The company's CellFX System allows for the adjustment of four key treatment parameters: pulse duration, pulse amplitude, pulse frequency, and the number of pulses, depending on the target tissue, application and desired treatment outcome.

QAD is a provider of cloud-based enterprise software solutions for manufacturing companies across the automotive, life sciences, consumer products, food and beverage, technology and industrial products industries. The company's solutions, called QAD Enterprise Applications, enable measurement and control of primary business processes that support operational requirements, including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. The company also provides services including consulting, deployment, training, technical, development and integration to facilitate adoption of its cloud Enterprise Applications solution.

Rafael Holdings owns interests in commercial real estate assets and clinical stage pharmaceutical companies. The company's business consists of two reportable segments: Real Estate and Pharmaceuticals. The commercial real estate holdings consist of the building in Newark, NJ that serves as headquarters for the company and certain affiliated entities, car public garage, an office/data center building in Piscataway, NJ and a portion of a building in Israel. The pharmaceutical holdings include Rafael Pharmaceuticals, Inc., which is a clinical-stage, oncology-focused, pharmaceutical company and LipoMedix Pharmaceuticals Ltd., which is a clinical-stage oncological pharmaceutical company based in Israel.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit targets primarily within the RAS and mTOR signaling pathways.

Sharps Compliance is a healthcare waste management provider focusing on regulated waste streams including medical, pharmaceutical and hazardous. The company's primary solutions include: Sharps Recovery System?, which is a solution for the containment, transportation, treatment and tracking of regulated medical waste generated outside the hospital and health care facility setting; TakeAway Medication Recovery System?, which facilitates the disposal of unused medications (including controlled substances) from users; and Universal Waste Shipback Systems, which is a jointly-promoted program for the collection, transportation and recycling of light bulbs, batteries and other mercury-containing devices.

SM Energy is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and natural gas liquids in the state of Texas. The company's operations are concentrated in the Midland Basin and South Texas.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company's product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. The company's second product candidate is mirdametinib, an oral, small molecule MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.

Translate Bio is a clinical-stage messenger RNA (mRNA) therapeutics company. The company is engaged in developing medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform (MRT platform), the company creates mRNA that encodes functional proteins. The company is developing its MRT product candidate for the lung, MRT5005, for the treatment of cystic fibrosi, and MRT5201, for the treatment of ornithine transcarbamylase deficiency.

Varex Imaging is a designer and manufacturer of X-ray imaging components. In its Medical business segment, the company designs, manufactures, sells and services X-ray imaging components for use in a range of radiographic or fluoroscopic imaging applications including computed tomography, mammography, oncology, cardiac, surgery, dental, and computer-aided detection. In its Industrial business segment, the company designs, manufactures, sells and services X-ray imaging products for use in several markets, including security applications, such as cargo screening at ports and borders and baggage screening at airports, and nondestructive testing and inspection applications used in several other markets.

Viking Therapeutics is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company's main clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta in development for patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's second clinical program's primary drug candidate, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in development for patients recovering from non-elective hip fracture surgery. The company is also developing VK0214 for X-linked adrenoleukodystrophy.

ZIOPHARM Oncology is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing immuno-oncology platforms that utilize cell- and gene-based therapies to treat patients with cancer. The company is developing immuno-oncology platform technologies for the treatment of various cancer types. The company's Sleeping Beauty platform is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T cells outside of the body for subsequent infusion. The company's Controlled IL-12 platform is designed to stimulate expression of interleukin 12, a regulator of the immune system to focus the patient's immune system to attack cancer cells.

Zix is a provider of cloud email security, productivity and compliance solutions. The company delivers a solutions for email encryption and data loss prevention (DLP), threat protection and archiving. The company serves organizations in the healthcare, financial services, and insurance and government sectors. Co.'s email encryption and DLP capabilities enable the secure exchange of email that includes sensitive information. Through a secure messaging service, Email Encryption allows an enterprise to use policy-driven rules to determine which email messages should be sent securely or quarantined for review to comply with regulations or company-defined policies.